Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check det
- Posted on June 1, 2026
- By Business News Today
- 0 Views
- 1 min read
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check det
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug targets multidrug-resistant Gram-negative pathogens and showed strong efficacy in Phase 3 trials. The approval highlights growing urgency around antimicrobial resistance and limited treatment options.
